TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

iStopMM study: A revised definition for LC MGUS in patients with preserved kidney function

Jan 30, 2024

Learning objective: After reading this article, learners will be able to recall the new definitions for light-chain monoclonal gammopathy of undetermined significance suggested by the iStopMM study.


Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

Question 1 of 1

What percentage reduction in the diagnosis of light-chain monoclonal gammopathy of undetermined significance was observed using the revised definitions compared with the standard definition?

A

B

C

D

Light-chain monoclonal gammopathy of undetermined significance (LC MGUS) is a form of MGUS characterized by an abnormal free light-chain (FLC) ratio with elevated serum free kappa and lambda light chains. The current definition for LC MGUS is based on a small cohort (n = 282) of healthy individuals. It has since been developed for individuals with impaired kidney function, but not those with preserved kidney function.1

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Einarsson Long presented results from the iStopMM study (NCT03327597), highlighting a novel definition for LC MGUS based on serum FLC measurements in individuals with normal kidney function (estimated glomerular filtration rate ≥60 mL/min/1.73 m2).

Design1

The overall trial design of the iStopMM study has been previously outlined by the Multiple Myeloma Hub.

The standard definition for LC MGUS in patients with preserved kidney function is:

  • serum kappa; 3.3–19.4 mg/L;
  • serum lambda; 5.7–26.3 mg/L; and
  • FLC ratio; 0.26–1.65.

This analysis aimed to redefine the reference intervals for individuals with preserved kidney function, to limit overdiagnosis of LC MGUS. Overall,

  • 75,422 individuals from the total iStopMM population aged ≥40 were screened for LC MGUS using serum protein electrophoresis, immunofixation, and serum FLC assay;
  • 41,882 individuals who had normal kidney function were screened for FLC reference intervals; and
  • two-thirds of MGUS cases were randomized for follow-up.

Results1

  • A correlation was observed between increasing age and serum kappa FLC (p = 0.27; p < 0.001), lambda FLC (p = 0.14; p < 0.001), and FLC ratio (p = 0.16; p < 0.001).
  • A revised set of reference values was recommended for individuals with normal kidney function (Table 1).

Table 1. Revised intervals by age*

FLC, free light chain.
*Adapted from Einarsson Long.1

Reference intervals, mg/L (unless otherwise specified)

Age <70 years
(n = 33,181)

Age >70 years
(n = 8,701)

Kappa

6.3–39.0

7.0–55.8

Lambda

5.9–36.7

6.4–48.0

FLC, ratio

0.44–2.16

0.46–2.59

  • Prevalence of LC MGUS based on the standard definition was 1.54% (95% confidence interval [CI], 1.46–1.63) compared with 0.26% (95% CI, 0.23–0.30) using the iStopMM criteria;
  • this equates to an 83% decrease in LC MGUS diagnosis with the novel criteria; and
  • individuals who met the standard criteria for LC MGUS but not the revised definition showed no progression within a 3.5-year follow-up period.

An outline of the revised definition for LC MGUS is shown in Figure 1.

Figure 1. Revised definition of LC MGUS* 

eGFR, estimated glomerular filtration rate; FLC, free-light chain; LC MGUS, light-chain monoclonal gammopathy of undetermined significance.
*Adapted from Einarsson Long.1

Conclusion

Previously, the standard reference intervals for LC MGUS diagnosis were based on a small cohort of patients and lead to inaccurate thresholds, especially for younger individuals. This revised definition of LC MGUS, based on the iStopMM study, demonstrated significantly lower rates of false positive diagnoses, which could reduce unnecessary health anxiety in patients and aid in the provision of healthcare resources.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...